Objectives: This study reports the influence of colorectal neoplasia on methylation intermediates and folate concentrations in human colonic mucosa, as well as systemic measures of folate status, to examine biomarkers and possible mechanisms of folaterelated carcinogenesis. Subjects: A total of 47 patients were selected from those previously diagnosed with adenocarcinoma of the colorectum undergoing surgery. For each individual, we obtained a biopsy of the adenocarcinoma and a biopsy of normal appearing mucosa, to perform an intra-individual comparison. Results: The 'methylation' ratio (S-adenosylmethionine/S-adenosylhomocysteine (SAH)) was lower in pathological tissue vs normal mucosa (P ¼ 0.08), mainly due to a much higher SAH concentration (Po0.005). Colonic folate concentration was significantly diminished in malignant tissue (Po0.0001). Plasma homocysteine concentration was within the normal to high range, and folate and vitamin B12 plasma concentrations were within the low to normal range as compared with normative values. Conclusion: Our results contribute to the hypothesis that altered DNA methylation and methyl metabolism is associated with colorectal neoplasia.
Introduction
Over the past two decades, evidence from different types of research -epidemiological and animal models -has increasingly supported the concept that a diminished folate status is associated with the development of colorectal cancer (Kim, 1999; Giovannucci, 2002) .
The studies in humans so far have relied mostly on either dietary folate intake or blood folate concentrations as a measure of folate status. Whether such measurements accurately assess the concentration of folate in the colonic mucosa, which contains the cells of origin in colorectal cancer, is still questionable (Meenan et al., 1997; Kim et al., 1998) .
The exact mechanism by which folate is related to colorectal carcinogenesis has not been elucidated, although several candidates have been proposed. Folate is an essential factor in a number of critical cellular metabolic pathways that involve the transfer of one-carbon groups, which include the de novo biosynthesis of purines and thymidylate and the transfer of methyl groups. In consequence, folate deficiency could contribute to DNA damage, instability of the chromatin, impaired DNA repair or aberrant patterns of genomic and/or gene-specific DNA methylation, all of which are considered to enhance carcinogenesis (Wainfan and Poirier, 1992; Laird and Jaenisch, 1996; Mason, 2000, 2002) .
Although in the past decade the understanding of folaterelated carcinogenesis has increased, several issues remain unknown and unconfirmed. In consequence, a recent position paper states that to establish whether there is a role for folate in the prevention of malignancy, further urgent research is needed, especially clinical trials with hard end points or validated intermediate end points, such as polyps (de Meer et al., 2006) .
In the present study, we were able to evaluate some critical biomarkers of methionine metabolism in colonic neoplasic mucosa vs mucosa of normal appearance from the same individuals with diagnosed colorectal carcinogenesis. The aim of the study was to investigate whether these biomarkers could contribute to the understanding of the mechanisms involved in folate-related carcinogenesis.
Subjects
The study was reviewed and approved by the Human Investigations Committees of the Fundació n Jiménez Díaz Hospital (Madrid, Spain) and the San Pablo-CEU University (Madrid, Spain), following the principles embodied in the Declaration of Helsinki.
Subjects included in the study were selected from those previously diagnosed with adenocarcinoma of the colorectum undergoing surgery. Subjects were excluded from the study if they were suffering from a concomitant carcinogenesis process, hepatitis B/C, and/or Crohn's disease and ulcerative colitis. The use of folate antagonists such as methotrexate, antiepileptics or sulfasalazine was also considered an exclusion criterion. In addition, subjects who had been taking folate supplements containing 4400 mg folate per day were also excluded from the study.
Finally, the subjects included in the study were a total of 47 (30 men with a mean age of 71.572.1 years, and 17 women with a mean age of 71.973.9 years). At the time of surgery, biopsies were taken immediately from the resected colon, before it was referred to the pathologist for histological diagnosis. For each individual, a biopsy of the malignant tissue and a biopsy of normal appearing mucosa, taken at least 10 cm away from the mucosal abnormality, were obtained, immediately placed in foil packets and frozen in liquid nitrogen and then stored at À701C until assayed.
Results and discussion
At present there is considerable evidence that aberrant DNA methylation plays an integral role in oncogenesis: first, a decreased level of genomic methylation is a common finding in tumourigenesis; second, gene-specific hypomethylation has been observed within critical genes in neoplastic tissues. This decrease in genomic methylation occurs generally early in carcinogenesis, and seems to precede the better described mutation and deletion events that are shown later in the evolution of cancer Mason, 2000, 2002) .
In colorectal cancer, genomic DNA hypomethylation has been reported in tumour tissue (Goelz et al., 1985; Cravo et al., 1994) and there are also reports of decreased DNA methylation in normal appearing colonic mucosa from individuals with colorectal cancer or adenoma (Cravo et al., 1994; Pufulete et al., 2003) . However, very few studies have attempted to study changes in methylation intermediates, either systemic or tissue specific, in humans diagnosed with colorectal cancer.
In the present study, we investigated some critical intermediates of methionine metabolism, related to DNA methylation, to contribute to the understanding of the mechanisms involved in colorectal cancer, as well as to the search for convenient biomarkers of disease. These intermediates include folate, S-adenosylmethionine (SAM), S-adenosylhomocysteine (SAH), homocysteine and vitamin B12 (Figure 1) .
Folate concentration in biopsies from colonic mucosa is shown in Table 1 . Folate status, measured as tissue concentration, was significantly diminished in malignant tissue compared with normal appearing mucosa, from the same individuals undergoing surgery (Po0.0001). Plasma folate concentrations (6.270.17 nmol/l) fall within the normal range as compared with reference values (Varela-Moreiras, 2003) .
In a recent review, Kim (2004) concludes that the portfolio of evidence from animal, human and in vitro studies suggests that the effects of folate deficiency on DNA methylation are highly complex; appear to depend on cell type, target organ Methionine metabolism and colorectal cancer E Alonso-Aperte et al and stage of transformation; and are gene and site specific. Taken together, currently available data from animal and cell studies pertaining to the effects of folate deficiency on DNA methylation in the colon are inconsistent and do not support the hypothesis that folate deficiency induces DNA hypomethylation in the colon. In humans, the effect of folate deficiency of a physiologically and clinically relevant degree on DNA methylation in the colorectum has not been studied (Kim, 2004) . Therefore, although aberrant patterns and dysregulation of DNA methylation have been proposed as a leading mechanism by which folate depletion enhances the development of colorectal cancer, currently available data from animal and human studies remain controversial (Stempak et al., 2005) . In our study, we assessed folate concentrations in plasma and colonic mucosa, both normal appearing and neoplasic, to contribute to the description of folate status in diagnosed colorectal cancer. The finding that colonic folate concentration was more than 50% significantly reduced in adenocarcinomas compared with normal mucosa contributes to the idea that persons at risk of developing colorectal cancer have localized folate depletion compared with those not at risk. In accordance with this idea, Kim et al. (1998) found that subjects with adenomatous polyps in their colons had significantly lower colonic mucosal folate concentrations in the normal mucosa of the rectosigmoid junction than did those who had hyperplastic polyps. However, the differences found in tissue may not be apparent to a significant degree when conventional indicators of systemic folate status are used. Thus, in our study, plasma folate concentration did not reflect an overt, systemic folate deficiency in our patients, as compared with normative values (Institute of Medicine, 2000; Varela-Moreiras, 2003) . In this same direction, serum and red cell folate concentrations did not differ significantly in patients with adenomas or hyperplastic polyps (Kim et al., 1998) .
To further study the hypomethylation effect associated with colorectal cancer, we measured the tissue content of the methyl donor, SAM, and the product of transmethylation reactions, SAH (Figure 1, Table 1 ). The ratio of SAM/SAH is frequently used as an indicator of cellular methylation capacity, whereby a decrease in the ratio usually predicts reduced cellular methylation potential (Hoffman et al., 1979) . However, it is unclear from the SAM/SAH ratio whether substrate insufficiency, product inhibition or both are required to negatively affect cellular methylation capacity. SAM is the body's chief physiological methyl donor, but it is questionable if whether reductions in SAM alone are causally related to cellular hypomethylation, because it has been demonstrated that identical decreases in the SAM/SAH ratio are conditionally associated with reduced methylation capacity depending of the absolute value of SAH (Caudill et al., 2001; James et al., 2002) . SAH is a potent product inhibitor of most SAM-dependent methyltransferase enzymes by binding to the active site with higher affinity than SAM (Hoffman et al., 1980) . Therefore, an evaluation of the tissuespecific alterations in the individual components may provide a more accurate reflection of methylation capacity than the SAM/SAH ratio.
The so-called methylation ratio (SAM/SAH) was decreased (28.8%) in malignant tissue when compared with normal mucosa in our study, although results do not reach statistical significance (P ¼ 0.084) ( Table 1 ). This percentage is much lower to the one observed for the increase in SAH in malignant tissue (97.0%, Po0.005). Therefore, in our study, individual SAH seems to be a better predictor of cellular methylation capacity than the SAM/SAH ratio. In addition, we did not find a decline in SAM concentration, but a significant increase (88.9%, Po0.0001) in SAM content in malignant tissue compared with normal mucosa. Taken together, our results show that DNA hypomethylation in adenocarcinomas could be explained through an increase in SAH concentration in the tissue of interest.
The primary importance of SAH as a mediator of methylation status was demonstrated in a human study in healthy volunteers in which it was found that increased levels of plasma homocysteine and plasma SAH, without concurrent changes in SAM, were associated with lymphocyte DNA hypomethylation (Yi et al., 2000) . In patients with vascular disease, Castro et al. (2003) reported significantly higher plasma homocysteine and SAH concentrations in association with leukocyte DNA hypomethylation, without concomitant changes in plasma SAM concentration. In an animal model, a decrease in the SAM/SAH ratio was predictive of reduced methylation capacity only when associated with an increase in SAH; a decrease in the SAM/SAH ratio due to SAM depletion alone was not sufficient to affect DNA methylation (Caudill et al., 2001) . These results support the possibility that SAH concentrations may provide a sensitive biomarker for cellular methylation status.
Paradoxically, we found a significantly higher SAM concentration in malignant tissue as compared with normal mucosa, although folate concentration in this same tissue was dramatically diminished. This result was unexpected and counterintuitive, since SAM receives the methyl group from folate and folate deficiency has been consistently associated with reduced SAM concentrations in different animal and cell studies. Nonetheless, in a recent in vitro model, a severe folate deficiency increased intracellular SAM concentrations in untransformed NIH/3T3 mouse fibroblast cells and HCT116 human colon adenocarcinoma cells (Stempak et al., 2005) . This increase in SAM concentration could be due to the SAHmediated inhibition of methyltransferases. Moreover, James et al. (2002) hypothesizes that SAH could act as bioregulator of one carbon metabolism through an upregulation of methionine adenosyltransferase II (Figure 1) , the enzyme that catalyses SAM synthesis in extrahepatic tissues and fetal liver, as first proposed by Cantoni (1985) . These effects could be plausible explanations for the increase in SAM concentration observed in malignant tissue in our study. One corollary of our results, however, poses the intriguing question that SAM concentrations may not be adequate biomarkers of methylation capacity.
Homocysteine and vitamin B12 concentrations were measured in plasma from our patients. The mean value for plasma homocysteine (10.570.26 mmol/l) is well below the 14.0 mmol/l, usually recognized as the high-risk cut-off value for hyperhomocysteinemia and related diseases. Vitamin B12 mean plasma concentration (203.773.03 pmol/l) is well above the cut-off range for vitamin B12 deficiency (Institute of Medicine, 2000) and our results match values published by Pufulete et al. (2003) in patients diagnosed with colorectal cancer.
Conclusion
In summary, our data show that in neoplasic colonic mucosa folate concentration is diminished and SAM and SAH concentrations are increased, as compared with normal colonic mucosa. These data clearly support the hypothesis of the importance of altered DNA methylation, as a consequence of inadequate folate status, as a major pathway towards cancer. However, the direction of changes of methionine cycle intermediates in the colon is not uniformly consistent with the known biochemical effect of folate on the methionine cycle pathway. Therefore, more studies in humans are warranted to confirm these alterations. Since colorrectal cancer is not associated with a severe systemic folate deficiency, as measured through blood folate levels or homocysteinemia, the measurement of genomic DNA methylation and the measurement of SAH hold promise as functional biomarkers related to folate status in colorectal cancer.
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